For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH treatment plan.

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...

Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with ...

Discover why Wave Life Sciences Ltd. is a high-risk, high-reward biotech with unique RNA therapies for AATD, obesity, and ...

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

They’re definitely easier and more affordable than injectables, but do they work as well? Here’s what you need to know.